K Eberhardt1, E Fex. 1. Department of Rheumatology, Lund University Hospital, Sweden.
Abstract
OBJECTIVE: To investigate the clinical course in early rheumatoid arthritis (RA) patients followed prospectively, to relate course to outcome after 5 yr, and to try to identify prognostic features. METHODS: A total of 183 patients with definite RA and a mean disease duration of 11 months were included. Of these, 75% were rheumatoid factor (RF) positive; 85% carried the shared epitope, 32% on both alleles. Most patients were assessed every 6 months. Disability was evaluated with the Health Assessment Questionnaire (HAQ) and radiographic findings according to Larsen. Remission was defined in two ways: with the American Rheumatism Association (ARA) criteria and as 'no arthritis at least at one follow-up visit'. RESULTS: Twenty per cent achieved ARA-defined remission periods of at least 6 months duration; 21 were spontaneous and 18 drug induced. Average length of remission was 20.5 months. The remission periods constituted 7% of follow-up for all patients. Another 36% achieved remission according to the second definition. All 56% were considered to have a relapsing-remitting disease pattern, in contrast to the remaining 44% with a persistent disease pattern. More patients with persistent disease were treated with disease-modifying anti-rheumatic drugs (DMARDs) and had also received a larger number of different drugs. Outcome after 5 yr regarding disability, joint inflammation and joint damage was worse for patients with persistent disease. Neither ARA-defined remission nor disease pattern could be accurately predicted. CONCLUSIONS: Long-term ARA-defined remission was rare, constituting 7% of follow-up for the entire cohort. For those 20% achieving remission, this period represented 34% of their follow-up. A total of 56% had a relapsing-remitting disease pattern and 44% had a persistent disease pattern. This classification had prognostic implications with persistency being a bad prognostic sign.
OBJECTIVE: To investigate the clinical course in early rheumatoid arthritis (RA) patients followed prospectively, to relate course to outcome after 5 yr, and to try to identify prognostic features. METHODS: A total of 183 patients with definite RA and a mean disease duration of 11 months were included. Of these, 75% were rheumatoid factor (RF) positive; 85% carried the shared epitope, 32% on both alleles. Most patients were assessed every 6 months. Disability was evaluated with the Health Assessment Questionnaire (HAQ) and radiographic findings according to Larsen. Remission was defined in two ways: with the American Rheumatism Association (ARA) criteria and as 'no arthritis at least at one follow-up visit'. RESULTS: Twenty per cent achieved ARA-defined remission periods of at least 6 months duration; 21 were spontaneous and 18 drug induced. Average length of remission was 20.5 months. The remission periods constituted 7% of follow-up for all patients. Another 36% achieved remission according to the second definition. All 56% were considered to have a relapsing-remitting disease pattern, in contrast to the remaining 44% with a persistent disease pattern. More patients with persistent disease were treated with disease-modifying anti-rheumatic drugs (DMARDs) and had also received a larger number of different drugs. Outcome after 5 yr regarding disability, joint inflammation and joint damage was worse for patients with persistent disease. Neither ARA-defined remission nor disease pattern could be accurately predicted. CONCLUSIONS: Long-term ARA-defined remission was rare, constituting 7% of follow-up for the entire cohort. For those 20% achieving remission, this period represented 34% of their follow-up. A total of 56% had a relapsing-remitting disease pattern and 44% had a persistent disease pattern. This classification had prognostic implications with persistency being a bad prognostic sign.
Authors: A Stockman; B D Tait; R Wolfe; C A Brand; M J Rowley; M D Varney; R Buchbinder; K D Muirden Journal: Rheumatol Int Date: 2005-09-07 Impact factor: 2.631
Authors: Annemarie C Brescia; Megan M Simonds; Suzanne M McCahan; Paul T Fawcett; Carlos D Rose Journal: Arthritis Rheumatol Date: 2014-05 Impact factor: 10.995
Authors: G Cohen; L Gossec; M Dougados; A Cantagrel; P Goupille; J P Daures; N Rincheval; B Combe Journal: Ann Rheum Dis Date: 2006-08-25 Impact factor: 19.103
Authors: Nick J Bansback; Dean A Regier; Roberta Ara; Alan Brennan; Kamran Shojania; John M Esdaile; Aslam H Anis; Carlo A Marra Journal: Drugs Date: 2005 Impact factor: 9.546
Authors: Licia Maria Henrique da Mota; Leopoldo Luiz Dos Santos Neto; Ana Cristina V Oliveira; Ivânio Alves Pereira; Rufus W Burlingame; Henri A Ménard; Ieda Maria Magalhães Laurindo Journal: Rheumatol Int Date: 2011-12-25 Impact factor: 2.631
Authors: L Gossec; M Dougados; P Goupille; A Cantagrel; J Sibilia; O Meyer; J Sany; J-P Daurès; B Combe Journal: Ann Rheum Dis Date: 2004-06 Impact factor: 19.103
Authors: S M M Verstappen; G A van Albada-Kuipers; J W J Bijlsma; A A M Blaauw; Y Schenk; H C M Haanen; J W G Jacobs Journal: Ann Rheum Dis Date: 2004-05-06 Impact factor: 19.103